- Home
- Products
Columvi (Glofitamab-gxbm)
Columvi (Glofitamab-gxbm)
- Medicine Name: Columvi
- Generic Name: Glofitamab-gxbm
- Dosage Form & Strength: Injection – 2.5 mg/2.5 mL (1 mg/mL) and 10 mg/10 mL (1 mg/mL) in single-use vials
- Manufactured By: Genentech, Inc.
Columvi (glofitamab-gxbm) is an innovative bispecific antibody therapy indicated for adults with relapsed or refractory diffuse large B-cell lymphoma (DLBCL) or large B-cell lymphoma (LBCL) who have received at least two prior lines of systemic treatment.
Dosage Guidelines:
Administered via intravenous infusion over 12 cycles (each cycle lasts 21 days). Treatment starts with step-up dosing to reduce the risk of cytokine release syndrome (CRS).
- Cycle 1:
- Day 1: Obinutuzumab 1,000 mg pre-treatment (7 days prior to Columvi)
- Day 8: Columvi 2.5 mg
- Day 15: Columvi 10 mg
- Day 1: Obinutuzumab 1,000 mg pre-treatment (7 days prior to Columvi)
- Cycle 2 to 12:
Day 1 of each cycle: Columvi 30 mg
Infusion duration for the first full dose is around four hours, followed by 10 hours of monitoring. Treatment continues until completion of 12 cycles, disease progression, or unacceptable toxicity.
- Cytokine Release Syndrome (CRS): Can be severe or fatal. Administer in facilities equipped to manage CRS. Adhere strictly to the step-up dosing schedule and premedication.
- Neurologic Toxicity (ICANS): May cause serious neurotoxicity. Monitor patients for changes in mental status or neurologic symptoms.
- Infection Risk: Do not administer during active infections. Follow infection prophylaxis guidelines and monitor throughout treatment.
- Tumor Flare Risk: Patients with bulky disease or tumors near vital organs may experience tumor flare. Closely observe during early cycles.
- Pregnancy Risk: May cause fetal harm. Advise effective contraception during treatment and for 30 days after the last dose.
Required for Import to India:
- Prescription from a licensed oncologist
- Diagnostic reports
- Government-issued photo ID of the patient
Order Confirmation:
Orders are processed only after receiving all necessary documentation and import permit (if applicable).
Availability:
Columvi is not locally available in retail pharmacies across India. GlobalRareMeds facilitates patient access under the Named Patient Import Program, sourcing from certified suppliers in the US, EU, and other regulated markets.
GlobalRareMeds sources Columvi from globally trusted pharmaceutical networks and ensures compliant delivery across India.
Prescriptions are verified and fulfilled through our fulfillment center in Ambernath, Thane District, Maharashtra. Delivery is supported in cities including Mumbai, Delhi, Bengaluru, Chennai, Kolkata, Hyderabad, Pune, and more.
Contact Details:
📧 info@globalraremeds.com
📞 +91-99675 15602
📱 WhatsApp: +91-99675 15602
What is the generic name of Columvi?
Glofitamab-gxbm.
Who manufactures Columvi?
Columvi is manufactured by Genentech, Inc.
Is Columvi approved by the FDA?
Yes, it was approved by the FDA on June 15, 2023.
In what dosage forms is Columvi available?
Columvi is supplied as 2.5 mg/2.5 mL and 10 mg/10 mL single-dose vials for intravenous infusion.
What are the common side effects of Columvi?
The most frequently reported side effects include CRS, skin rash, bone/muscle pain, and fatigue.
What is the cost of Columvi in India?
Cost varies depending on source and dosage requirement. Contact GlobalRareMeds for updated pricing and procurement assistance.
How should Columvi be stored?
Store at 2°C–8°C (36°F–46°F) in the original packaging. Protect from light. Do not freeze or shake.
Can I legally purchase Columvi online in India?
Yes, Columvi can be imported legally through GlobalRareMeds under the Named Patient Program with a valid prescription and documentation.
Contact Patient Support
If you have questions about your order, need assistance with documentation, or require support with medicine availability, our GlobalRareMeds Patient Support Team is here to help. We aim to respond within 24 hours, Monday to Friday, between 9:00 AM and 10:00 AM IST.
info@globalraremeds.com
Phone
+91 99675 15602
+91 99675 15602
Disclaimer
All trademarks, brands, and product names featured on this website are the property of their respective owners. GlobalRareMeds does not claim ownership or affiliation unless explicitly stated. Our role is to provide reliable and transparent access to difficult-to-source medicines through named-patient import services, based on valid prescriptions and legal requirements.
The product-related content on this website is shared to the best of our knowledge, compiled from publicly available sources and regulatory documents. However, GlobalRareMeds does not guarantee the accuracy, completeness, or timeliness of this information. We strongly recommend that all medical decisions, including usage and dosage, be made only in consultation with the prescribing doctor. GlobalRareMeds assumes no responsibility for consequences arising from reliance on this information without appropriate medical guidance
